NEWPORT BEACH, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”) today announced that it has filed its Quarterly Report on Form 10-Q (“Quarterly Report”) for the three months ended March 31, 2025, with the U.S. Securities and Exchange Commission (“SEC”). The Quarterly Report is available on the SEC’s website at www.sec.gov under the company’s filings, as well as on the Company’s investor relations website. Management believes the Company is we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-41875 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) (State of incorporation) (I.R.S. Employer Identification No.) Graydon Bensler 120 Newport Center Drive, Suite 249 Newport Beach, C ...

NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. (“Northstrive”), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists. The Company filed the following fo ...

NEWPORT BEACH, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), today announced the filing of four novel patent applications for its two candidates EL-22 and EL-32. These patent applications cover the animal market, as well as treating muscle loss in obese patients, both as standalone and combination therapies alongside GLP-1 receptor agonists. The Company filed the following fo ...

The full interview featuring Deniel Mero can be viewed here. NEWPORT BEACH, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Northstrive Biosciences Inc. ("Northstrive"), a subsidiary of PMGC Holdings Inc. (NASDAQ: ELAB) (the "Company," "PMGC," "we," or "our"), is proud to announce that Co-Founder Deniel Mero was recently featured in an exclusive interview hosted by Bear Bull Traders, a leading global online stock trading community for professional and aspiring traders. During the interview, Mr. Mero discussed No ...

Core Viewpoint - Northstrive Biosciences Inc. has received preliminary feedback from the FDA regarding its pre-IND meeting, indicating support for the IND submission to initiate a Phase 2 clinical study for EL-22 in combination with GLP-1 receptor agonists [1][2][6] Group 1: FDA Feedback and Clinical Development - The FDA agreed that Northstrive's pharmacology studies support the activity of EL-22 [2] - The FDA indicated that Northstrive's nonclinical studies are adequate to support the safety and activity of EL-22 in overweight and obese populations [2] - Data from Northstrive's Phase 1 study and completed nonclinical studies are sufficient to allow the initiation of the proposed Phase 2 clinical trial [2] Group 2: EL-22 Overview - EL-22 is a novel, patent-pending engineered probiotic designed to express myostatin on its surface, targeting the myostatin pathway to support muscle health [3] - Preclinical studies have shown significant physiological and functional improvements in mdx mice, a model for Duchenne muscular dystrophy [3][4] - EL-22 has completed a Phase 1 clinical trial in South Korea, demonstrating it to be generally well-tolerated and safe in healthy volunteers [3] Group 3: Company Strategy and Future Plans - Northstrive aims to file the Investigational New Drug application in 2025 and subsequently initiate a Phase 2 clinical trial for obesity treatment [2] - The company is in discussions with cGMP manufacturing partners to prepare for the production of EL-22 [2] - The development of EL-22 addresses the need for preserving muscle in patients undergoing GLP-1 therapies for weight loss [4]

NEWPORT BEACH, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ:PMGC) (the "Company," "PMGC," "we," or "us"), a diversified public holding company, is pleased to announce the signing of a non-binding Letter of Intent ("LOI") to acquire a U.S.-based, cash-flow positive information technology ("IT") custom packaging company. About the Target Company Founded in 2011 and headquartered in Southern California, the Target is a well-established provider of custom packaging solutions for IT prod ...

Northstrive Biosciences and Yuva Biosciences’ collaboration will leverage MitoNova™, YuvaBio’s proprietary mitochondrial science-focused artificial intelligence platform, to discover and develop novel pharmaceutical treatments for obesity, type 2 diabetes and other cardiometabolic conditions.Northstrive and Yuva Biosciences will compile a library of small molecule candidates that promote mitochondrial health and target the root cause of aging at the cellular level. NEWPORT BEACH, Calif., April 10, 2025 (GL ...

Core Viewpoint - PMGC Holdings Inc. has filed its Annual Report for the fiscal year ended December 31, 2024, with the SEC, highlighting its commitment to innovative solutions and long-term shareholder value [1][2]. Company Overview - PMGC is a diversified holding company that manages a portfolio through strategic acquisitions, investments, and development across various industries [3]. - The current portfolio includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. Strategic Initiatives - The company is actively seeking acquisition opportunities that can drive meaningful revenue growth and enhance shareholder value as part of its strategic growth initiatives [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 001-41875 PMGC HOLDINGS INC. (Exact name of registrant as specified in its charter) Nevada 33-2382547 (State or other jurisdiction of incorporation or organization) FORM 10-K ☒ ANNUAL REPORT PURUANT TO SECTION 13 OR 15(d) OF ...